Introduction: When to Seek Diagnostic Evaluation

If you notice a sudden rash that looks like targets or bull’s-eyes on your skin, especially on your hands, feet, arms, or legs, it’s important to see a doctor. Erythema multiforme is a skin condition that develops as your body’s reaction to an infection or medication, and while it often resolves on its own, proper diagnosis ensures you receive appropriate care and helps rule out more serious conditions.^[1]

You should seek medical evaluation promptly if the rash spreads rapidly, develops blisters, or appears inside your mouth, on your lips, eyes, or genital areas. These symptoms may indicate a more severe form of the condition called erythema multiforme major, which can affect the mucous membranes—the moist linings of body openings—and may require more intensive treatment.^[1] Anyone experiencing fever, body aches, difficulty eating or drinking, or pain when urinating alongside a rash should request an urgent appointment with their healthcare provider.^[4]

Early diagnosis is particularly important if the rash appeared shortly after starting a new medication. In such cases, identifying the triggering drug and stopping it quickly can prevent the condition from worsening. However, never stop taking prescribed medications without first consulting your doctor, as some medicines need to be discontinued gradually or require substitution with alternatives.^[4]

People who have experienced erythema multiforme before, especially if it keeps recurring, should also consult their doctor. Repeated episodes might be linked to recurrent infections, particularly the herpes simplex virus that causes cold sores, and preventive treatments may be available to reduce future occurrences.^[1]

Classic Diagnostic Methods

Diagnosing erythema multiforme is primarily based on recognizing the characteristic appearance of the rash during a physical examination. Most healthcare providers can identify the condition simply by looking at the distinctive skin lesions, which is why careful visual inspection forms the cornerstone of diagnosis.^[1]

Physical Examination and Clinical Recognition

During your medical visit, the doctor will carefully examine your skin and ask detailed questions about your symptoms and recent health history. The hallmark feature doctors look for is the “target lesion”—a round mark on your skin that resembles a bull’s-eye on a dartboard. These targets typically have three distinct zones: a dark center (which may be dusky red or purple), surrounded by a lighter pale ring, with a red ring around the outer edge.^[5] This three-ring pattern is considered the classic presentation of erythema multiforme.

The distribution of the rash also provides important diagnostic clues. Erythema multiforme lesions most commonly appear symmetrically on both sides of the body, particularly on the hands, feet, arms, and legs, with a preference for the outer surfaces of the limbs where they extend. The rash typically starts at the body’s periphery—the hands and feet—and spreads inward toward the trunk over a period of about three to four days.^[3] This pattern of spread helps distinguish erythema multiforme from other skin conditions that may look similar initially.

Your doctor will also check whether mucous membranes are involved. In erythema multiforme major, the lips may be covered with crusts, and raw, painful areas can appear inside the mouth, on the eyes, or on the genitals. The presence and extent of mucosal involvement—meaning damage to these moist membrane surfaces—helps determine whether you have the minor or major form of the condition, which influences treatment decisions.^[2]

Medical History Assessment

Understanding what triggered your erythema multiforme is crucial for proper management, so your healthcare provider will ask detailed questions about recent events. They will inquire about any infections you’ve had in the past few weeks, particularly cold sores caused by herpes simplex virus, or respiratory infections that might have been caused by bacteria called Mycoplasma pneumoniae, which can lead to lung infections like pneumonia.^[5] These infections are the most common triggers of erythema multiforme, with herpes simplex virus type 1 accounting for the majority of infection-related cases.^[3]

Your doctor will also review all medications you’ve taken recently, including over-the-counter drugs, supplements, and any new prescriptions started within the past two months. Medications cause less than 10% of erythema multiforme cases, but when they do trigger the condition, common culprits include nonsteroidal anti-inflammatory drugs like ibuprofen, antibiotics (especially sulfonamides, penicillins, and tetracyclines), anticonvulsant medications used for seizures or nerve pain, and statins used to lower cholesterol.^[5] Identifying the offending medication is essential because continued exposure can worsen symptoms or lead to recurrence.

The timeline between potential triggers and symptom onset provides valuable diagnostic information. Infections typically precede the rash by one to two weeks, while medication reactions usually occur within one to four weeks of starting a new drug. However, if you’ve been exposed to the same medication before, symptoms can develop much faster—sometimes within just 48 hours of re-exposure.^[16]

Laboratory and Additional Testing

In most straightforward cases, no laboratory tests are necessary because the characteristic appearance of the target lesions is sufficient for diagnosis. However, when the diagnosis is uncertain or the presentation is atypical, doctors may order additional tests to confirm erythema multiforme or rule out other conditions.^[1]

Blood tests might be performed to check for evidence of recent infections. These tests can detect antibodies your immune system produces in response to viruses like herpes simplex or bacteria like Mycoplasma pneumoniae. Identifying an active or recent infection helps confirm the trigger and guide treatment, particularly if antiviral or antibiotic therapy might be beneficial.^[7]

When the diagnosis remains unclear after clinical examination, a skin biopsy may be performed. This procedure involves removing a small sample of affected skin tissue, which is then examined under a microscope by a specialist called a pathologist. The microscopic appearance of erythema multiforme shows specific patterns of inflammation and damage to skin cells that help distinguish it from similar-looking conditions.^[1] Biopsies are particularly useful when doctors need to differentiate erythema multiforme from more serious conditions like Stevens-Johnson syndrome, which requires different treatment approaches.

Testing a tissue sample can also reveal the presence of viral DNA fragments in the skin, which supports the diagnosis when herpes simplex virus is suspected as the trigger. Specialized laboratory techniques can identify these viral genetic materials even when the person no longer has active cold sores.^[3]

Differentiating from Similar Conditions

An important part of diagnosing erythema multiforme involves ruling out other conditions that can look similar but require different treatments. One key distinction is between erythema multiforme and urticaria (hives). While both can cause raised, red lesions on the skin, individual urticarial lesions typically come and go within 24 hours, whereas erythema multiforme lesions remain fixed in the same location for at least seven days before beginning to heal.^[5] This difference in how long individual spots last helps doctors determine which condition they’re dealing with.

Perhaps the most critical distinction is separating erythema multiforme from Stevens-Johnson syndrome and toxic epidermal necrolysis, which are more severe conditions almost always caused by medications. While these conditions were once thought to be on the same spectrum as erythema multiforme, medical research has established they are separate diseases with different underlying mechanisms.^[5] Stevens-Johnson syndrome typically presents with widespread red or purplish flat spots (macules) with blisters, rather than the raised target lesions seen in erythema multiforme. Additionally, in Stevens-Johnson syndrome, larger areas of skin can detach and peel, and mucosal involvement tends to be more extensive and severe.^[7]

The location and appearance of skin lesions help make this distinction. Erythema multiforme targets are typically raised, have well-defined borders, and concentrate on the extremities. In contrast, the lesions in Stevens-Johnson syndrome are usually flatter, have poorly defined borders, tend to merge together, and are more prominent on the trunk and face.^[7] Making this distinction correctly is vital because Stevens-Johnson syndrome and toxic epidermal necrolysis are medical emergencies requiring immediate hospitalization and intensive care.

Diagnostics for Clinical Trial Qualification

While erythema multiforme is not a condition that typically involves clinical trials in the same way as chronic diseases or cancers, research studies evaluating new treatments or better understanding the disease mechanisms do exist. When such studies are conducted, specific diagnostic criteria are used to ensure that participants truly have erythema multiforme and can be accurately categorized by disease severity.

Standard Diagnostic Criteria for Research

Clinical trials evaluating erythema multiforme treatments or studying disease patterns require clearly defined inclusion criteria. Participants must have confirmed erythema multiforme, typically diagnosed using the established classification system that categorizes cases as either erythema multiforme minor or major based on the extent of mucosal membrane involvement.^[2]

For research purposes, the diagnosis must be based on the presence of typical target lesions with the characteristic three-zone appearance, or at least atypical target lesions with two zones of color variation. The lesions should show the expected distribution pattern, primarily affecting the extremities with symmetrical presentation. Studies may require photographic documentation of the rash to allow independent verification of the diagnosis by expert reviewers.^[3]

Classification into minor versus major forms depends on mucosal involvement. Erythema multiforme minor includes only skin lesions with minimal or no mucosal membrane involvement and typically lacks systemic symptoms like fever or joint pain. Erythema multiforme major involves one or more mucous membranes—commonly the mouth, eyes, or genital areas—and often includes systemic symptoms such as fever, headache, or joint discomfort.^[1] Clinical trials often specify which form of the disease is being studied, as treatment needs may differ.

Exclusion of Similar Conditions

Research protocols typically require ruling out Stevens-Johnson syndrome and toxic epidermal necrolysis before enrolling participants. This distinction is crucial because these are separate diseases with different causes, treatments, and prognoses. Studies may use specific criteria such as the percentage of body surface area affected by skin detachment (less than 10% in erythema multiforme) and the predominant lesion type (raised targets in erythema multiforme versus flat macules in Stevens-Johnson syndrome) to make this differentiation.^[7]

Identifying Triggers for Subgroup Analysis

Clinical trials often categorize participants based on the suspected trigger of their erythema multiforme. This categorization allows researchers to evaluate whether treatments work differently depending on the cause. Studies may require laboratory confirmation of herpes simplex virus infection through blood tests showing antibodies or through detection of viral DNA in skin samples.^[3] Similarly, evidence of recent Mycoplasma pneumoniae infection might be confirmed through specific antibody tests or other microbiological methods.

For medication-associated cases, careful documentation of all drugs taken in the weeks before symptom onset is essential. Research protocols typically require a clear temporal relationship between medication exposure and symptom development, with symptoms appearing within one to four weeks of starting a new medication (or within 48 hours if previously exposed to the same drug).^[16]

Baseline Assessment and Disease Monitoring

Before entering a clinical trial, participants undergo comprehensive baseline evaluation to document the severity and extent of their condition. This assessment typically includes detailed measurement of how much body surface area is affected by the rash, the number and type of target lesions present, and the extent of mucosal involvement if any. Standardized scales or scoring systems may be used to objectively quantify disease severity, allowing researchers to track changes over time and evaluate treatment effectiveness.

For studies focusing on recurrent erythema multiforme, participants might need to document the frequency of past episodes, the triggers identified for previous occurrences, and any treatments previously tried. This historical information helps researchers understand disease patterns and identify which patients are most likely to benefit from preventive treatments, such as long-term antiviral therapy for herpes-associated recurrent cases.^[5]